Trial reportBMC neurology2026
Effect of high-frequency stellate ganglion block on sleep and affective symptoms in insomnia disorder: a prospective pilot study.
Trial report in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsomnia disorder imposes substantial health burdens, while current pharmacotherapies risk adverse effects and cognitive behavioral therapy face implementation barriers. Stellate ganglion block (SGB) modulates autonomic function and sleep architecture but lacks evidence for optimized protocols. This pilot study evaluates the feasibility and preliminary clinical outcomes of a high-frequency SGB protocol for improving sleep, anxiety, and depression in insomnia disorder.
methodsA single-center, prospective single-arm trial enrolled 72 patients diagnosed with insomnia disorder according to ICSD-3 criteria. Participants received daily ultrasound-guided SGB (0.8% lidocaine, 3 ml) unilaterally for 10 consecutive days. Outcomes included Pittsburgh Sleep Quality Index (PSQI), Generalized Anxiety Disorder-7 (GAD-7), and Patient Health Questionnaire-9 (PHQ-9) scores assessed at baseline (T1), immediately post-intervention (T2), and at 4-week (T3) and 12-week (T4) follow-up. Statistical analysis used repeated-measures ANOVA.
resultsThe mean PSQI score improved from 15.35 ± 2.39 at baseline to 10.59 ± 3.23 post-intervention (mean reduction 4.76, 95% CI [4.04, 5.49], P < 0.001), exceeding the minimal clinically important difference (MCID) of 3 points. This improvement was sustained at 12 weeks (mean reduction 4.08, 95% CI [3.32, 4.85]). Anxiety (GAD-7: baseline 7.47 ± 4.57) and depression (PHQ-9: baseline 9.07 ± 5.72) scores showed statistically significant reductions post-treatment (GAD-7: T2-T4 P < 0.05; PHQ-9: T2-T4 P < 0.05). However, the magnitude of improvement did not reach established MCID (4 points for GAD-7, 5 points for PHQ-9), with mean reductions ranging from 0.99 to 2.18 points for GAD-7 and 1.72 to 2.04 points for PHQ-9. This suggests that while statistically detectable, the clinical relevance of affective symptom improvements may be limited, particularly given the relatively mild baseline symptom severity.
conclusionThis pilot study demonstrates that a high-frequency SGB protocol is feasible to implement in patients with insomnia disorder. Within-group improvements in sleep quality that exceeded the MCID were observed and sustained through 12-week follow-up. However, due to the uncontrolled single-arm design, these results should be interpreted as hypothesis-generating rather than confirmatory. The observed improvements may be attributable to placebo effects, natural history, or regression to the mean. These findings provide effect size estimates to inform the design of future randomized sham-controlled trials, which are necessary to establish causal efficacy.
trial registrationThis study was registered on the Chinese Clinical Trial Registry on March 19th, 2025 (Registration No.: ChiCTR2500099219).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.